Clinical implications for girdin protein expression in breast cancer

Cancer Investigation

Volumn 29, Issue 6, 2011, Pages 405-410

  Ling, Yun ^a   Jiang, Ping ^a   Cui, Su Ping ^a   Ren, Ya Li ^b   Zhu, Sai Nan ^b   Yang, Jing Ping ^a   Du, Juan ^a   Zhang, Yan ^a   Liu, Jian Ying ^a   Zhang, Bo ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b PEKING UNIVERSITY   (China)

Author keywords

Breast cancer; CerbB2; Girdin

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GIRDIN; ONCOPROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GROWTH; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAINING;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MICROFILAMENT PROTEINS; MIDDLE AGED; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL; VESICULAR TRANSPORT PROTEINS;

EID: 79958237182     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2011.568568     Document Type: Article

References (20)

1. Anim JT, John B, Abdulsathar SS, Prasad A, Saji T, Akhtar N, Ali V, Al-Saleh M. (Relationship between the expression of various markers and prognostic factors in breast cancer. Acta Histochem 2005;107:87-93. (Pubitemid 40799007)
2. Kasami M, Uematsu T, Honda M, Yabuzaki T, Sanuki J, Uchida Y, Sugimura H. Comparison of estrogen receptor, progesterone receptor and Her-2 status in breast cancer pre- and postneoadjuvant chemotherapy. Breast 2008;17:523-527.
3. Rody A, Diallo R, Poremba C, Speich R, Wuelfing P, Kissler S, Solbach C, Kiesel L, Jackisch C. Estrogen receptor alpha and beta, progesterone receptor, pS2 and HER-2/neu expression delineate different subgroups in ductal carcinoma in situ of the breast. Oncol Rep 2004;12:695-699.
4. Briest S, Stearns V. Tamoxifen metabolism and its effect on endocrine treatment of breast cancer. Clin Adv Hematol Oncol 2009;7:185-192.
5. Korkaya H, Wicha, MS. HER-2, notch, and breast cancer stem cells: targeting an axis of evil. Clin Cancer Res 2009;15:1845-1847.
6. Hussein MR, Abd-Elwahed SR, Abdulwahed AR. Alterations of estrogen receptors, progesterone receptors and c-CerbB2 oncogene protein expression in ductal carcinomas of the breast. Cell Biol Int 2008;32:698-707.
7. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev 2005;5:341-354. (Pubitemid 40637826)
8. Manning BD, Cantley, LC. AKT/PKB signaling: navigating downstream. Cell 2007;129:1261-1274. (Pubitemid 46962095)
9. Bublil EM, Yarden Y, The EGF receptor family: spearheading a merger of signaling and therapeutics. Curr Opin Cell Biol 2007;19:124-134. (Pubitemid 46386405)
10. Ghosh P, Garcia-Marcos M, Bornheimer SJ, Farquhar, MG. Activation of Galphai3 triggers cell migration via regulation of GIV. J Cell Biol 2008;182:381-393.
11. Jiang P, Enomoto A, Jijiwa M, Kato T, Hasegawa T, Ishida M, Sato T,Asai N,Murakumo Y, TakahashiM.An actin-binding protein girdin regulates the motility of breast cancer cells. Cancer Res 2008;68:1310-1318. (Pubitemid 351346837)
12. Enomoto A, Ping J, Takahashi M, Girdin, a novel actin-binding protein, and its family of proteins possess versatile functions in the Akt and Wnt signaling pathways. Ann NY Acad Sci 2006;1086:169-184. (Pubitemid 47084384)
13. Ghosh P, Beas AO, Bornheimer SJ, Garcia-Marcos M, Forry EP, Johannson C, Ear J, Jung BH, Cabrera B, Carethers JM, Farquhar MG. A G{alpha}i-GIV molecular complex binds epidermal growth factor receptor and determines whether cellsmigrate or proliferate. Mol Biol Cell 2010;21(13):2338-2354.
14. Garcia-Marcos M, Jung BH, Ear J, Cabrera B, Carethers JM, Ghosh P. Expression of GIV/Girdin, a metastasis-related protein, predicts patient survival in colon cancer. FASEB J 2011;25:590-599.
15. Baselga J, Swain, SM. Novel anticancer targets: revisiting CerbB2 and discovering ERBB3. Nat Rev Cancer 2009;9:463-475.
16. Park K, Han S, Kim HJ, Kim J, Shin E. (HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry. Histopathology 2006;8:702- 707.
17. Yamauchi H, CristofanilliM, Nakamura S, et al.Molecular targets for treatment of inflammatory breast cancer. Nat Rev Clin Oncology 2009;6:387-394.
18. Nagata Y, Lan KH, Zhou X, TanM, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, Hortobagyi GN, Hung MC, Yu D. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004;6:117-127. (Pubitemid 39485684)
19. Enomoto A,Murakami H, Asai N,Morone N,Watanabe T, Kawai K, Murakumo Y, Usukura J, Kaibuchi K, Takahashi M. Akt/PKB regulates actin organization and cellmotility via Girdin/APE. Dev Cell 2005;9(3):389-402. (Pubitemid 41235808)
20. Kitamura T, Asai N, Enomoto A, Morone N, Watanabe T, Kawai K,Murakumo Y, Usukura J, Kaibuchi K, Takahashi M. Regulation of VEGF-mediated angiogenesis by the Akt/PKB substrateGirdin. Nat Cell Biol 2008;10:329-337. (Pubitemid 351331020)